: iStockAnalyst.com Symbols Feed

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

Credit Market Overview: Nov 24, 2009

Tue, 24 Nov 2009 12:39:09 GMT

Whether we are currently in the eye of an economic storm the back wall of which is still lurking with prime residential and commercial mortgage defaults providing the knockout blow to an already weakened financial defense network, or as some say, the green shoots are turning into saplings, stocks have made their run up and credit spreads their run down providing some with reasonable returns for the year.[More...]

10 Conviction Buy Ideas From Our Top Managers

Mon, 16 Nov 2009 17:23:40 GMT

The holdings of a majority of our Ultimate Stock-Pickers yield 10 5-Star stocks.[More...]

The Week In Review: The Bull In China's R&D Shop

Sat, 14 Nov 2009 17:54:40 GMT

China currently ranks number two in the world in the number of scientific papers published and is quickly catching up with the US; China started a $1.3 billion fund to encourage clusters of emerging industries;[More...]

Diversify Away With EFA!

Tue, 10 Nov 2009 21:55:58 GMT

Diversify Your Portfolio Outside the US Asset allocation is the most influential factor on investment outcome. There have been growing signs that the worst of the global crisis might have passed. While the US dollar may continue to weaken and the US loses significance in the global landscape, an allocation to other developed markets is deemed necessary. After all, 76% of global GDP is outside the US.[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

The Week in Review: Major Investments

Sun, 08 Nov 2009 01:33:43 GMT

Novartis made a five-year, $1 billion China commitment, building up its Shanghai R&D center and marketing efforts; Novartis will also spend $250 million to expand its global technical center in Changshu, and pay $125 million to buy a 85% stake in vaccine maker Zhejiang Tianyuan; Roche opened a new $500 million biologics manufacturing facility in Singapore; Microbix and Hunan Biopharmaceutical Co. will construct a $200 million flu vaccine facility;[More...]

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Momenta Pharma (MNTA): Timing Uncertain, Approval Likely for M-Enoxaparin

Tue, 06 Oct 2009 21:44:54 GMT

Momenta Pharma (NASDAQ: MNTA) presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for the Company, including an update on the FDA status for M-Enoxaparin.[More...]

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Fri, 02 Oct 2009 16:55:00 GMT

On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP).[More...]

Evening Standard, London, market report column

Thu, 03 Dec 2009 18:48:00 GMT

Dec. 3--Commodity stocks should keep rising next year, but the best is behind the financials.
That's the opinion of Goldman Sachs, whose strategy suggestions for 2010 were being circulated in the City today.
Shares in London rose, with the FTSE putting on 30.71 points to 5358.10 as the banks bounced back from yesterday's losses.

[More...]

FDA OK's Agriflu seasonal flu vaccine

Mon, 30 Nov 2009 13:11:00 GMT

FDA OK's Agriflu seasonal flu vaccine[More...]

Tiffany, J. Crew, TiVo, Incyte are big movers

Wed, 25 Nov 2009 21:07:00 GMT

NEW YORK - The following stocks were among those that moved substantially or traded heavily Wednesday on the New York Stock Exchange:
Strong sales overseas and contained costs led the luxury jeweler to raise its profit outlook ahead of the holiday season.
J. Crew Group Inc., up $3.20 to $44.05

[More...]

Seasonal flu vaccine supplies spur worries

Tue, 24 Nov 2009 15:20:00 GMT

Seasonal flu vaccine supplies spur worries[More...]

New Brunswick government reimburses Lucentis(x) for residents suffering from leading cause of age-related vision loss

Mon, 16 Nov 2009 17:46:00 GMT

Wet AMD patients now have access to first medication to improve vision
DORVAL, QC, Nov. 16 /CNW Telbec/ - New Brunswickers with wet age- related macular degeneration (AMD) now have access to the new treatment Lucentis(x) (ranibizumab injection) through the New Brunswick Prescription Drug Program (NBPDP) - an important development that demonstrates the government's commitment to ensuring New Brunswick residents diagnosed with the leading cause of adult-onset vision loss receive optimal treatment.
New Brunswick now joins Newfoundland and Labrador as the only second Atlantic province to reimburse Lucentis(x), giving patients for whom the diagnosis of wet AMD could previously have meant rapidly deteriorating central vision loss and possibly even blindness , real hope to preserve and even improve vision and to maintain their independence.

[More...]

QLT Announces Third Quarter Results for 2009

Tue, 27 Oct 2009 11:48:00 GMT

QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM
VANCOUVER, Oct. 27 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial results for the third quarter ended September 30, 2009.
For the third quarter and nine months ended September 30, 2009, QLT is reporting the results of our divested QLT USA business as one line item called Income from Discontinued Operations on our statements of operations.

[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 17:12:00 GMT

UPI NewsTrack TopNews[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 12:29:00 GMT

UPI NewsTrack TopNews[More...]

CDC: 16 million flu vaccine doses shipped

Sat, 24 Oct 2009 12:07:00 GMT

CDC: 16 million flu vaccine doses shipped[More...]

UPI NewsTrack Health and Science News

Tue, 15 Sep 2009 21:46:00 GMT

UPI NewsTrack Health and Science News[More...]

AspenBio to Present at the Lazard Capital Market 6th Annual Healthcare Conference

Fri, 13 Nov 2009 15:50:00 GMT

AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, has been invited to present at the Lazard Capital Market 6th Annual Healthcare Conference to be held November 17-18, 2009 at The St. Regis Hotel New York, NY.
Company management is scheduled to present on Tuesday, November 17, 2009 at 9:25 a.m. Eastern time, with one-on-one meetings held throughout the day.
The company has a development and marketing agreement with Novartis Animal Health (NYSE: NVS) for the bovine species.

[More...]

Bernhard Hampl, Ph.D. Elected to Serve As Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.

Tue, 03 Nov 2009 04:47:00 GMT

Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009.
Dr. Hampl, also named as Executive Chairman of the Board, succeeds current Chairman Dr. Ulf M. Schneider.
I am pleased to be joining the Board of Fresenius Kabi Pharmaceuticals Holding and look forward to using my experience to expand APP's pipeline, while exploring new opportunities that will position it for future growth," said Dr. Hampl.

[More...]

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on PCP, NVS, SPR, MUR, PG and OSK

Tue, 27 Oct 2009 11:10:00 GMT

RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment.
Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.
We have recently begun in-depth analysis of the following equities & their respective sectors:

[More...]

Novus Energy Inc. grants performance warrants and options

Fri, 04 Sep 2009 17:03:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.

Wed, 26 Aug 2009 13:46:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones.
ProStrakan will exclusively supply FORTESTA to Endo Pharmaceuticals in the U.S. for an undisclosed supply price.

[More...]

Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes

Wed, 26 Aug 2009 11:50:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary.
The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.
The tender offer is being made pursuant to an Offer to Purchase, dated August 26, 2009, and related Letter of Transmittal, dated August 26, 2009, which set forth the terms and conditions and a more detailed description of the tender offer.

[More...]

Novus Energy Inc. announces third quarter 2009 results

Tue, 25 Aug 2009 21:57:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009

Tue, 25 Aug 2009 15:45:00 GMT

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis . PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.[More...]

BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

Thu, 06 Aug 2009 10:48:00 GMT

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), The Leading Provider of Real Estate to the Life Science Industry(R), announced today that its board of directors and corporate officers will ring The Closing Bell(R) at the New York Stock Exchange on Thursday, August 6, 2009 at 4:00 p.m. Eastern Time to commemorate the fifth anniversary of the company's initial public offering.
BioMed's founders, Alan D. Gold, Chairman and Chief Executive Officer, and Gary A. Kreitzer, Executive Vice President, General Counsel and Director, will preside over the ringing of The Closing Bell(R).
"This is a great day for our team," said Mr. Gold.

[More...]

Standard & Poor's annonce des modifications a l'indice compose S&P/TSX de croissance

Tue, 04 Aug 2009 21:37:00 GMT

TORONTO, le 4 aout /CNW/ - Standard & Poor's apportera les modifications suivantes a l'indice compose S&P/TSX de croissance le mardi 4 aout 2009, apres la cloture des marches :[More...]